FY2025 Earnings Estimate for PRE Issued By Cantor Fitzgerald

Prenetics Global Limited (NASDAQ:PRE) – Equities research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Prenetics Global in a note issued to investors on Thursday, November 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($2.22) for the year, up from their previous estimate of ($2.61). Cantor Fitzgerald currently has a “Overweight” rating and a $32.00 price target on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global’s FY2026 earnings at $1.52 EPS.

A number of other analysts have also recently issued reports on PRE. Wall Street Zen raised Prenetics Global from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $32.00.

Prenetics Global Stock Up 4.4%

Prenetics Global stock opened at $12.31 on Monday. Prenetics Global has a 12 month low of $3.09 and a 12 month high of $17.99. The stock has a market cap of $207.18 million, a P/E ratio of -5.00 and a beta of 0.35. The company’s fifty day simple moving average is $13.31 and its 200-day simple moving average is $9.80.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative net margin of 60.70% and a negative return on equity of 30.12%. The firm had revenue of $23.56 million for the quarter, compared to analyst estimates of $26.00 million. Prenetics Global has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Prenetics Global

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in Prenetics Global during the third quarter valued at approximately $65,000. Stevens Capital Partners bought a new stake in shares of Prenetics Global during the 2nd quarter worth $137,000. UBS Group AG grew its stake in Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares during the last quarter. Aberdeen Group plc bought a new position in Prenetics Global in the 3rd quarter worth $979,000. Finally, Nomura Holdings Inc. raised its holdings in Prenetics Global by 3.3% in the 1st quarter. Nomura Holdings Inc. now owns 333,528 shares of the company’s stock worth $1,307,000 after acquiring an additional 10,576 shares during the period. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.